6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-3-ethoxycarbonylquinoline-2-acetic acid ethyl ester | 158147-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-3-ethoxycarbonylquinoline-2-acetic acid ethyl ester
• 英文别名: ethyl 6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-3-ethoxycarbonylquinoline-2-acetate；ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3-ethoxycarbonylquinoline-2-acetate；ethyl 4-(3,4-dimethoxyphenyl)-2-(2-ethoxy-2-oxoethyl)-6,7-dimethoxyquinoline-3-carboxylate
• CAS: 158147-45-6
• 化学式: C₂₆H₂₉NO₈
• 分子量: 483.518
• InChiKey: WSAWQIAATQVLKG-UHFFFAOYSA-N

物化性质

• 沸点：
  582.6±50.0 °C(predicted)
• 密度：
  1.203±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-3-ethoxycarbonylquinoline-2-acetic acid ethyl ester 在 lithium aluminium tetrahydride 、 三溴化磷 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 1.5h， 生成 3-喹啉羧酸,2-(2-溴乙基)-4-(3,4-二甲氧苯基)-6,7-二甲氧基-,乙基酯
  参考文献：
  名称：

  Studies on Disease-Modifying Antirheumatic Drugs:  Synthesis of Novel Quinoline and Quinazoline Derivatives and Their Anti-inflammatory Effect

  摘要：

  In the course of our study aimed at developing new types of DMARDs (disease-modifying antirheumatic drugs), we found that quinoline derivative 1a had a potent anti-inflammatory effect in an adjuvant arthritis (AA) rat model, starting from the potent bone resorption inhibitors justicidins as the lead compounds. Further modification of la was performed, and various quinoline and quinazoline derivatives having a heteroaryl moiety on the alkyl side chain at the 2-position of the skeleton were prepared. These compounds were evaluated for antiinflammatory effects using the AA rat model. Most of these compounds, especially those having an imidazole or a triazole moiety on the 2-alkyl chain, exhibited a potent effect. Among the compounds synthesized, ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-yl-methyl)quinoline-3-carboxylate (12d), having an ED(50) value of 2.6 mg/kg/day (anti-inflammatory effect in an AA rat model, po), was selected as a candidate for further investigation. In vitro, 12d inhibited mitogen-induced proliferation at 10(-7)-10(-5) M but not prostaglandin E(2) production at 10(-5) M. Moreover, 12d preferentially inhibited the IFN-gamma production by Th1-type clones over the IL-4 production by Th2-type clones. This preferential suppression of Th1 cytokine production is considered the essential immunomodulating action of 12d for the present. Synthesis and structure-activity relationships for this novel series of quinoline and quinazoline derivatives are detailed.

  DOI：

  10.1021/jm9509408
• 作为产物：
  描述：

  1,3-丙酮二羧酸二乙酯 、 (2-amino-4,5-dimethoxyphenyl)(3,4-dimethoxyphenyl)methanone 在 硫酸 、 溶剂黄146 作用下， 反应 3.0h， 以56%的产率得到6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-3-ethoxycarbonylquinoline-2-acetic acid ethyl ester
  参考文献：
  名称：

  Studies on Disease-Modifying Antirheumatic Drugs:  Synthesis of Novel Quinoline and Quinazoline Derivatives and Their Anti-inflammatory Effect

  摘要：

  In the course of our study aimed at developing new types of DMARDs (disease-modifying antirheumatic drugs), we found that quinoline derivative 1a had a potent anti-inflammatory effect in an adjuvant arthritis (AA) rat model, starting from the potent bone resorption inhibitors justicidins as the lead compounds. Further modification of la was performed, and various quinoline and quinazoline derivatives having a heteroaryl moiety on the alkyl side chain at the 2-position of the skeleton were prepared. These compounds were evaluated for antiinflammatory effects using the AA rat model. Most of these compounds, especially those having an imidazole or a triazole moiety on the 2-alkyl chain, exhibited a potent effect. Among the compounds synthesized, ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-yl-methyl)quinoline-3-carboxylate (12d), having an ED(50) value of 2.6 mg/kg/day (anti-inflammatory effect in an AA rat model, po), was selected as a candidate for further investigation. In vitro, 12d inhibited mitogen-induced proliferation at 10(-7)-10(-5) M but not prostaglandin E(2) production at 10(-5) M. Moreover, 12d preferentially inhibited the IFN-gamma production by Th1-type clones over the IL-4 production by Th2-type clones. This preferential suppression of Th1 cytokine production is considered the essential immunomodulating action of 12d for the present. Synthesis and structure-activity relationships for this novel series of quinoline and quinazoline derivatives are detailed.

  DOI：

  10.1021/jm9509408

文献信息

• Quinoline or quinazoline derivatives, their production and use
  申请人：Takeda Chemical Industries

  公开号：US05436247A1

  公开（公告）日：1995-07-25

  A compound represented by the general formula: ##STR1## wherein Y represents a nitrogen atom or C--G (G represents a carboxyl group which may be esterified); ring R is a nitrogen-containing unsaturated heterocyclic group which may be substituted or unsubstituted; each of rings A and B may have a substituent; n represents an integer from 1 to 4; k represents the integer 0 or 1, or a salt thereof, which serves well as an anti-inflammatory agent, particularly a therapeutic agent for arthritis.

  一种由通式表示的化合物：##STR1## 其中Y代表一个氮原子或C--G（G代表一个可能酯化的羧基）；环R是一个含氮的不饱和杂环基团，可以被取代或未取代；环A和环B中的每一个都可以有一个取代基；n代表一个从1到4的整数；k代表整数0或1，或其盐，可作为一种抗炎药物，特别是治疗关节炎的药物。
• Pharmaceutical composition containing quinoline or quinazoline
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05719157A1

  公开（公告）日：1998-02-17

  The present invention provides a pharmaceutical composition for inhibiting bone resorption or for preventing or treating osteoporosis which comprises a quinoline or quinazoine derivative as an active ingredient.

  本发明提供了一种用于抑制骨吸收或预防/治疗骨质疏松症的药物组合物，其包含喹啉或喹啉衍生物作为活性成分。
• Pharmaceutical composition containing quinoline or quinazoline derivatives
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0634169A1

  公开（公告）日：1995-01-18

  The present invention provides a pharmaceutical composition for inhibiting bone resorption or for preventing or treating osteoporosis which comprises a quinoline or quinazoine derivative as an active ingredient.

  本发明提供了一种用于抑制骨吸收或预防或治疗骨质疏松症的药物组合物，其活性成分包括喹啉或喹唑啉衍生物。
• Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0634169B1

  公开（公告）日：2000-01-05
• QUINOLINE OR QUINAZOLINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS, IN PARTICULAR FOR TREATING ARTHRITIS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0749426A1

  公开（公告）日：1996-12-27